Adjuvant probiotics and the intestinal microbiome: Enhancing vaccines and immunotherapy outcomes

Vaccines

Volumn 5, Issue 4, 2017, Pages

  Vitetta, Luis ^a,b   Saltzman, Emma Tali ^a,b   Thomsen, Michael ^a   Nikov, Tessa ^b   Hall, Sean ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Medlab   (Australia)

Author keywords

Immunological tolerance; Infections; Probiotics; Vaccines

Indexed keywords

BACTERIAL VACCINE; COMPLEMENT COMPONENT C3D RECEPTOR; IMMUNOGLOBULIN A; INFLAMMASOME; INTERLEUKIN 1BETA; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PREBIOTIC AGENT; PROBIOTIC AGENT; TETANUS TOXOID; TICK BORNE ENCEPHALITIS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DYSBIOSIS; HOMEOSTASIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFLUENZA; INTESTINE FLORA; LACTOBACILLUS GASSERI; LACTOBACILLUS PARACASEI; LUNG INFECTION; NONHUMAN; PHAGOCYTOSIS; REVIEW; SOCIAL STATUS; T LYMPHOCYTE; TETANUS; TH1 CELL; TICK BORNE ENCEPHALITIS;

EID: 85041914945     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines5040050     Document Type: Review

References (88)

1. Plotkin, S. History of vaccination. Proc. Natl. Acad. Sci. USA 2014, 111, 12283–12287. [CrossRef] [PubMed]
2. Arbeter, A.M.; Starr, S.E.; Plotkin, S.A. Varicella vaccine studies in healthy children and adults. Pediatrics 1986, 78, 748–756. [PubMed]
3. Kuter, B.J.; Weibel, R.E.; Guess, H.A.; Matthews, H.; Morton, D.H.; Neff, B.J.; Provost, P.J.; Watson, B.A.; Starr, S.E.; Plotkin, S.A. Oka/Merck varicella vaccine in healthy children: Final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991, 9, 643–647. [CrossRef]
4. Youngster, I.; Kozer, E.; Lazarovitch, Z.; Broide, E.; Goldman, M. Probiotics and the immunological response to infant vaccinations: A prospective, placebo controlled pilot study. Arch. Dis. Child. 2011, 96, 345–349. [CrossRef] [PubMed]
5. Cooper, N.R.; Nemerow, G.R. The role of antibody and complement in the control of viral infections. J. Investig. Dermatol. 1984, 83, 121s–127s. [CrossRef] [PubMed]
6. Bacchetta, R.; Gregori, S.; Roncarolo, M.G. Cd4+ regulatory T cells: Mechanisms of induction and effector function. Autoimmun. Rev. 2005, 4, 491–496. [CrossRef] [PubMed]
7. Igietseme, J.U.; Eko, F.O.; He, Q.; Black, C.M. Antibody regulation of tcell immunity: Implications for vaccine strategies against intracellular pathogens. Expert Rev. Vaccines 2004, 3, 23–34. [CrossRef] [PubMed]
8. Sender, R.; Fuchs, S.; Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016, 14, e1002533. [CrossRef] [PubMed]
9. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486, 207–214.
10. Okumura, R.; Takeda, K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis. Exp. Mol. Med. 2017, 49, e338. [CrossRef] [PubMed]
11. Linares, D.M.; Ross, P.; Stanton, C. Beneficial microbes: The pharmacy in the gut. Bioengineered 2016, 7, 11–20. [CrossRef] [PubMed]
12. Vitetta, L.; Hall, S.; Linnane, A.W. Live probiotic cultures and the gastrointestinal tract: Symbiotic preservation of tolerance whilst attenuating pathogenicity. Front. Cell. Infect. Microbiol. 2014, 4, 143. [CrossRef] [PubMed]
13. Vitetta, L.; Palacios, T.; Hall, S.; Coulson, S. Gastrointestinal tract commensal bacteria and probiotics: Influence on end-organ physiology. Prog. Drug Res. 2015, 70, 1–33. [PubMed]
14. Ozen, M.; Dinleyici, E.C. The history of probiotics: The untold story. Benef. Microbes 2015, 6, 159–165. [CrossRef] [PubMed]
15. Pereira, B.I.; Akbar, A.N. Convergence of innate and adaptive immunity during human aging. Front. Immunol. 2016, 7, 445. [CrossRef] [PubMed]
16. Klein, A.; Friedrich, U.; Vogelsang, H.; Jahreis, G. Lactobacillus acidophilus 74–2 and bifidobacterium animalis subsp lactis DGCC 420 modulate unspecific cellular immune response in healthy adults. Eur. J. Clin. Nutr. 2008, 62, 584–593. [CrossRef] [PubMed]
17. Gill, H.S.; Rutherfurd, K.J.; Prasad, J.; Gopal, P.K. Enhancement of natural and acquired immunity by lactobacillus rhamnosus (HN001), lactobacillus acidophilus (HN017) and bifidobacterium lactis (hn019). Br. J. Nutr. 2000, 83, 167–176. [CrossRef] [PubMed]
18. Siegrist, C.-A. 2-Vaccine Immunology A2—Plotkin, Stanley A. In Vaccines, 6th ed.; Orenstein, W.A., Offit, P.A., Eds.; W.B. Saunders: London, UK, 2013; pp. 14–32.
19. Peterson, L.W.; Artis, D. Intestinal epithelial cells: Regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 2014, 14, 141–153. [CrossRef] [PubMed]
20. Robinson, K.; Deng, Z.; Hou, Y.; Zhang, G. Regulation of the intestinal barrier function by host defense peptides. Front. Vet. Sci. 2015, 2, 57. [CrossRef] [PubMed]
21. World Health Organization. WHO Best Practices for Injections and Related Procedures Toolkit; WHO: Geneva, Switzerland, 2010.
22. Administraiton of Vaccines in Australia. 2016. Available online: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part2~handbook10-2-2 (accessed on 1 January 2017).
23. Mohr, E.; Siegrist, C.A. Vaccination in early life: Standing up to the challenges. Curr. Opin. Immunol. 2016, 41, 1–8. [CrossRef] [PubMed]
24. Siegrist, C.A. Neonatal and early life vaccinology. Vaccine 2001, 19, 3331–3346. [CrossRef]
25. Einhorn, M.S.; Weinberg, G.A.; Anderson, E.L.; Granoff, P.D.; Granoff, D.M. Immunogenicity in infants of haemophilus influenzae type B polysaccharide in a conjugate vaccine with neisseria meningitidis outer-membrane protein. Lancet 1986, 2, 299–302. [CrossRef]
26. Murasko, D.M.; Bernstein, E.D.; Gardner, E.M.; Gross, P.; Munk, G.; Dran, S.; Abrutyn, E. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol. 2002, 37, 427–439. [CrossRef]
27. Hainz, U.; Jenewein, B.; Asch, E.; Pfeiffer, K.P.; Berger, P.; Grubeck-Loebenstein, B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine 2005, 23, 3232–3235. [CrossRef] [PubMed]
28. Artz, A.S.; Ershler, W.B.; Longo, D.L. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev. 2003, 16, 308–318. [CrossRef] [PubMed]
29. Bogaert, D.; De Groot, R.; Hermans, P.W. Streptococcus pneumoniae colonisation: The key to pneumococcal disease. Lancet Infect. Dis. 2004, 4, 144–154. [CrossRef]
30. Bubnov, R.V.; Spivak, M.Y.; Lazarenko, L.M.; Bomba, A.; Boyko, N.V. Probiotics and immunity: Provisional role for personalized diets and disease prevention. EPMA J. 2015, 6, 14. [CrossRef] [PubMed]
31. Thomas, C.M.; Versalovic, J. Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes 2010, 1, 148–163. [CrossRef] [PubMed]
32. Pang, I.K.; Iwasaki, A. Control of antiviral immunity by pattern recognition and the microbiome. Immunol. Rev. 2012, 245, 209–226. [CrossRef] [PubMed]
33. GeurtsvanKessel, C.H.; Willart, M.A.; van Rijt, L.S.; Muskens, F.; Kool, M.; Baas, C.; Thielemans, K.; Bennett, C.; Clausen, B.E.; Hoogsteden, H.C.; et al. Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J. Exp. Med. 2008, 205, 1621–1634. [CrossRef] [PubMed]
34. Stoeker, L.; Nordone, S.; Gunderson, S.; Zhang, L.; Kajikawa, A.; LaVoy, A.; Miller, M.; Klaenhammer, T.R.; Dean, G.A. Assessment of lactobacillus gasseri as a candidate oral vaccine vector. Clin. Vaccine Immunol. 2011, 18, 1834–1844. [CrossRef] [PubMed]
35. Tsai, Y.T.; Cheng, P.C.; Liao, J.W.; Pan, T.M. Effect of the administration of lactobacillus paracasei subsp. Paracasei NTU 101 on peyer‘s patch-mediated mucosal immunity. Int. Immunopharmacol. 2010, 10, 791–798. [CrossRef] [PubMed]
36. Rosenberg, H.F.; Masterson, J.C.; Furuta, G.T. Eosinophils, probiotics, and the microbiome. J. Leukoc. Biol. 2016, 100, 881–888. [CrossRef] [PubMed]
37. Hajela, N.; Nair, G.B.; Ganguly, N.K. Are probiotics a feasible intervention for prevention of diarrhoea in the developing world? Gut Pathog. 2010, 2, 10. [CrossRef] [PubMed]
38. Oelschlaeger, T.A. Mechanisms of probiotic actions—A review. Int. J. Med. Microbiol. 2010, 300, 57–62. [CrossRef] [PubMed]
39. Johansson, M.A.; Sjogren, Y.M.; Persson, J.O.; Nilsson, C.; Sverremark-Ekstrom, E. Early colonization with a group of lactobacilli decreases the risk for allergy at five years of age despite allergic heredity. PLoS ONE 2011, 6, e23031. [CrossRef] [PubMed]
40. Westerholm-Ormio, M.; Vaarala, O.; Tiittanen, M.; Savilahti, E. Infiltration of Foxp3- and Toll-like receptor-4-positive cells in the intestines of children with food allergy. J. Pediatr. Gastroenterol. Nutr. 2010, 50, 367–376. [CrossRef] [PubMed]
41. Tang, M.L.; Lahtinen, S.J.; Boyle, R.J. Probiotics and prebiotics: Clinical effects in allergic disease. Curr. Opin. Pediatr. 2010, 22, 626–634. [CrossRef] [PubMed]
42. Amdekar, S.; Dwivedi, D.; Roy, P.; Kushwah, S.; Singh, V. Probiotics: Multifarious oral vaccine against infectious traumas. FEMS Immunol. Med. Microbiol. 2010, 58, 299–306. [CrossRef] [PubMed]
43. Vitetta, L.; Hall, S.; Coulson, S. Metabolic Interactions in the Gastrointestinal Tract (GIT): Host, commensal, probiotics, and bacteriophage influences. Microorganisms 2015, 3, 913–932. [CrossRef] [PubMed]
44. Ferreira, R.B.; Antunes, L.C.; Finlay, B.B. Should the human microbiome be considered when developing vaccines? PLoS Pathog. 2010, 6, e1001190. [CrossRef] [PubMed]
45. Valdez, Y.; Brown, E.M.; Finlay, B.B. Influence of the microbiota on vaccine effectiveness. Trends Immunol. 2014, 35, 526–537. [CrossRef] [PubMed]
46. Brezar, V.; Godot, V.; Cheng, L.; Su, L.; Levy, Y.; Seddiki, N. T-regulatory cells and vaccination “pay attention and do not neglect them”: Lessons from HIV and cancer vaccine trials. Vaccines 2016, 4, E30. [CrossRef] [PubMed]
47. Levine, M.M. Immunogenicity and efficacy of oral vaccines in developing countries: Lessons from a live cholera vaccine. BMC Biol. 2010, 8, 129. [CrossRef] [PubMed]
48. Korpe, P.S.; Petri, W.A., Jr. Environmental enteropathy: Critical implications of a poorly understood condition. Trends Mol. Med. 2012, 18, 328–336. [CrossRef] [PubMed]
49. Isolauri, E.; Joensuu, J.; Suomalainen, H.; Luomala, M.; Vesikari, T. Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by lactobacillus casei GG. Vaccine 1995, 13, 310–312. [CrossRef]
50. Matsuda, F.; Chowdairy, M.I.; Saha, A.; Asahara, T.; Nomoto, K.; Tarique, A.A.; Ahmed, T.; Nishibuchi, M.; Cravioto, A.; Qadri, F. Evaluation of a probiotics, bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, double-blind, placebo-controlled trial in bangladeshi children under 5 years of age. Vaccine 2011, 29, 1855–1858. [CrossRef] [PubMed]
51. Pérez, N.; Iannicelli, J.C.; Girard-Bosch, C.; González, S.; Varea, A.; Disalvo, L.; Apezteguia, M.; Pernas, J.; Vicentin, D.; Cravero, R. Effect of probiotic supplementation on immunoglobulins, isoagglutinins and antibody response in children of low socio-economic status. Eur. J. Nutr. 2010, 49, 173–179. [CrossRef] [PubMed]
52. Licciardi, P.V.; Ismail, I.H.; Balloch, A.; Mui, M.; Hoe, E.; Lamb, K.; Tang, M.L. Maternal supplementation with lgg reduces vaccine-specific immune responses in infants at high-risk of developing allergic disease. Front. Immunol. 2013, 4, 381. [CrossRef] [PubMed]
53. West, C.E.; Gothefors, L.; Granström, M.; Käyhty, H.; Hammarström, M.L.; Hernell, O. Effects of feeding probiotics during weaning on infections and antibody responses to diphtheria, tetanus and Hib vaccines. Pediatr. Allergy Immunol. 2008, 19, 53–60. [CrossRef] [PubMed]
54. Taylor, A.; Hale, J.; Wiltschut, J.; Lehmann, H.; Dunstan, J.A.; Prescott, S.L. Evaluation of the effects of probiotic supplementation from the neonatal period on innate immune development in infancy. Clin. Exp. Allergy 2006, 36, 1218–1226. [CrossRef] [PubMed]
55. Soh, S.E.; Ong, D.Q.; Gerez, I.; Zhang, X.; Chollate, P.; Shek, L.P.; Lee, B.W.; Aw, M. Effect of probiotic supplementation in the first 6 months of life on specific antibody responses to infant hepatitis B vaccination. Vaccine 2010, 28, 2577–2579. [CrossRef] [PubMed]
56. Kukkonen, K.; Nieminen, T.; Poussa, T.; Savilahti, E.; Kuitunen, M. Effect of probiotics on vaccine antibody responses in infancy—A randomized placebo-controlled double-blind trial. Pediatr. Allergy Immunol. 2006, 17, 416–421. [CrossRef] [PubMed]
57. Mohamadzadeh, M.; Olson, S.; Kalina, W.V.; Ruthel, G.; Demmin, G.L.; Warfield, K.L.; Bavari, S.; Klaenhammer, T.R. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. USA 2005, 102, 2880–2885. [CrossRef] [PubMed]
58. Mastrangeli, G.; Corinti, S.; Butteroni, C.; Afferni, C.; Bonura, A.; Boirivant, M.; Colombo, P.; Di Felice, G. Effects of live and inactivated VSL#3 probiotic preparations in the modulation of in vitro and in vivo allergen-induced Th2 responses. Int. Arch. Allergy Immunol. 2009, 150, 133–143. [PubMed]
59. Gibson, R.A.; Barclay, D.; Marshall, H.; Moulin, J.; Maire, J.C.; Makrides, M. Safety of supplementing infant formula with long-chain polyunsaturated fatty acids and bifidobacterium lactis in term infants: A randomised controlled trial. Br. J. Nutr. 2009, 101, 1706–1713. [CrossRef] [PubMed]
60. Link-Amster, H.; Rochat, F.; Saudan, K.Y.; Mignot, O.; Aeschlimann, J.M. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol. Med. Microbiol. 1994, 10, 55–63. [CrossRef] [PubMed]
61. Fang, H.; Elina, T.; Heikki, A.; Seppo, S. Modulation of humoral immune response through probiotic intake. FEMS Immunol. Med. Microbiol. 2000, 29, 47–52. [CrossRef] [PubMed]
62. Bunout, D.; Barrera, G.; Hirsch, S.; Gattas, V.; de la Maza, M.P.; Haschke, F.; Steenhout, P.; Klassen, P.; Hager, C.; Avendano, M.; et al. Effects of a nutritional supplement on the immune response and cytokine production in free-living chilean elderly. J. Parenter. Enter. Nutr. 2004, 28, 348–354. [CrossRef] [PubMed]
63. De Vrese, M.; Rautenberg, P.; Laue, C.; Koopmans, M.; Herremans, T.; Schrezenmeir, J. Probiotic bacteria stimulate virus-specific neutralizing antibodies following a booster polio vaccination. Eur. J. Nutr. 2005, 44, 406–413. [CrossRef] [PubMed]
64. Olivares, M.; Diaz-Ropero, M.P.; Sierra, S.; Lara-Villoslada, F.; Fonolla, J.; Navas, M.; Rodriguez, J.M.; Xaus, J. Oral intake of lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination. Nutrition 2007, 23, 254–260. [CrossRef] [PubMed]
65. Paineau, D.; Carcano, D.; Leyer, G.; Darquy, S.; Alyanakian, M.A.; Simoneau, G.; Bergmann, J.F.; Brassart, D.; Bornet, F.; Ouwehand, A.C. Effects of seven potential probiotic strains on specific immune responses in healthy adults: A double-blind, randomized, controlled trial. FEMS Immunol. Med. Microbiol. 2008, 53, 107–113. [CrossRef] [PubMed]
66. Boge, T.; Remigy, M.; Vaudaine, S.; Tanguy, J.; Bourdet-Sicard, R.; van der Werf, S. A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials. Vaccine 2009, 27, 5677–5684. [CrossRef] [PubMed]
67. Davidson, L.E.; Fiorino, A.M.; Snydman, D.R.; Hibberd, P.L. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: A randomized double-blind placebo-controlled trial. Eur. J. Clin. Nutr. 2011, 65, 501–507. [CrossRef] [PubMed]
68. Van Puyenbroeck, K.; Hens, N.; Coenen, S.; Michiels, B.; Beunckens, C.; Molenberghs, G.; Van Royen, P.; Verhoeven, V. Efficacy of daily intake of lactobacillus casei shirota on respiratory symptoms and influenza vaccination immune response: A randomized, double-blind, placebo-controlled trial in healthy elderly nursing home residents. Am. J. Clin. Nutr. 2012, 95, 1165–1171. [CrossRef] [PubMed]
69. Rizzardini, G.; Eskesen, D.; Calder, P.C.; Capetti, A.; Jespersen, L.; Clerici, M. Evaluation of the immune benefits of two probiotic strains bifidobacterium animalis ssp. Lactis, BB-12(R) and lactobacillus paracasei ssp. Paracasei, l. Casei 431(R) in an influenza vaccination model: A randomised, double-blind, placebo-controlled study. Br. J. Nutr. 2012, 107, 876–884. [CrossRef] [PubMed]
70. Bosch, M.; Mendez, M.; Perez, M.; Farran, A.; Fuentes, M.C.; Cune, J. Lactobacillus plantarum CECT7315 and CECT7316 stimulate immunoglobulin production after influenza vaccination in elderly. Nutr. Hosp. 2012, 27, 504–509. [PubMed]
71. Akatsu, H.; Arakawa, K.; Yamamoto, T.; Kanematsu, T.; Matsukawa, N.; Ohara, H.; Maruyama, M. Lactobacillus in jelly enhances the effect of influenza vaccination in elderly individuals. J. Am. Geriatr. Soc. 2013, 61, 1828–1830. [CrossRef] [PubMed]
72. Akatsu, H.; Iwabuchi, N.; Xiao, J.-Z.; Matsuyama, Z.; Kurihara, R.; Okuda, K.; Yamamoto, T.; Maruyama, M. Clinical effects of probiotic bifidobacterium longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding. J. Parenter. Enter. Nutr. 2013, 37, 631–640. [CrossRef] [PubMed]
73. Jespersen, L.; Tarnow, I.; Eskesen, D.; Morberg, C.M.; Michelsen, B.; Bugel, S.; Dragsted, L.O.; Rijkers, G.T.; Calder, P.C. Effect of lactobacillus paracasei subsp. Paracasei, l. Casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers: A randomized, double-blind, placebo-controlled, parallel-group study. Am. J. Clin. Nutr. 2015, 101, 1188–1196. [CrossRef] [PubMed]
74. Maruyama, M.; Abe, R.; Shimono, T.; Iwabuchi, N.; Abe, F.; Xiao, J.Z. The effects of non-viable lactobacillus on immune function in the elderly: A randomised, double-blind, placebo-controlled study. Int. J. Food Sci. Nutr. 2016, 67, 67–73. [CrossRef] [PubMed]
75. Sanchez, B.; Urdaci, M.C.; Margolles, A. Extracellular proteins secreted by probiotic bacteria as mediators of effects that promote mucosa-bacteria interactions. Microbiology 2010, 156, 3232–3242. [CrossRef] [PubMed]
76. Vitetta, L. Lactobacillus acidophilus restores functionality in uremic macrophages: Plausible or lacking evidence? Dig. Dis. Sci. 2016, 61, 1417–1419. [CrossRef] [PubMed]
77. Ivec, M.; Botic, T.; Koren, S.; Jakobsen, M.; Weingartl, H.; Cencic, A. Interactions of macrophages with probiotic bacteria lead to increased antiviral response against vesicular stomatitis virus. Antivir. Res. 2007, 75, 266–274. [CrossRef] [PubMed]
78. Dong, H.; Rowland, I.; Tuohy, K.M.; Thomas, L.V.; Yaqoob, P. Selective effects of lactobacillus casei shirota on t cell activation, natural killer cell activity and cytokine production. Clin. Exp. Immunol. 2010, 161, 378–388. [CrossRef] [PubMed]
79. Maidens, C.; Childs, C.; Przemska, A.; Dayel, I.B.; Yaqoob, P. Modulation of vaccine response by concomitant probiotic administration. Br. J. Clin. Pharmacol. 2013, 75, 663–670. [CrossRef] [PubMed]
80. Lei, W.T.; Shih, P.C.; Liu, S.J.; Lin, C.Y.; Yeh, T.L. Effect of probiotics and prebiotics on immune response to influenza vaccination in adults: A systematic review and meta-analysis of randomized controlled trials. Nutrients 2017, 9. [CrossRef] [PubMed]
81. Wang, R.F.; Miyahara, Y.; Wang, H.Y. Toll-like receptors and immune regulation: Implications for cancer therapy. Oncogene 2008, 27, 181–189. [CrossRef] [PubMed]
82. Wang, R.F.; Peng, G.; Wang, H.Y. Regulatory t cells and toll-like receptors in tumor immunity. Semin. Immunol. 2006, 18, 136–142. [CrossRef] [PubMed]
83. Pitt, J.M.; Vetizou, M.; Waldschmitt, N.; Kroemer, G.; Chamaillard, M.; Boneca, I.G.; Zitvogel, L. Fine-tuning cancer immunotherapy: Optimizing the gut microbiome. Cancer Res. 2016, 76, 4602–4607. [CrossRef] [PubMed]
84. Roy, S.; Trinchieri, G. Microbiota: A key orchestrator of cancer therapy. Nat. Rev. Cancer 2017, 17, 271–285. [CrossRef] [PubMed]
85. Routy, B.; Le Chatelier, E.; Derosa, L.; Duong, C.P.M.; Alou, M.T.; Daillere, R.; Fluckiger, A.; Messaoudene, M.; Rauber, C.; Roberti, M.P.; et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2017. [CrossRef] [PubMed]
86. Gopalakrishnan, V.; Spencer, C.N.; Nezi, L.; Reuben, A.; Andrews, M.C.; Karpinets, T.V.; Prieto, P.A.; Vicente, D.; Hoffman, K.; Wei, S.C.; et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2017. [CrossRef] [PubMed]
87. Alexander, J.L.; Wilson, I.D.; Teare, J.; Marchesi, J.R.; Nicholson, J.K.; Kinross, J.M. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 356–365. [CrossRef] [PubMed]
88. Banna, G.L.; Torino, F.; Marletta, F.; Santagati, M.; Salemi, R.; Cannarozzo, E.; Falzone, L.; Ferrau, F.; Libra, M. Lactobacillus rhamnosus GG: An overview to explore the rationale of its use in cancer. Front. Pharmacol. 2017, 8, 603. [CrossRef] [PubMed]